TW202327653A - 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物 - Google Patents

用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物 Download PDF

Info

Publication number
TW202327653A
TW202327653A TW111144466A TW111144466A TW202327653A TW 202327653 A TW202327653 A TW 202327653A TW 111144466 A TW111144466 A TW 111144466A TW 111144466 A TW111144466 A TW 111144466A TW 202327653 A TW202327653 A TW 202327653A
Authority
TW
Taiwan
Prior art keywords
antibody
chain variable
variable region
sequence
seq
Prior art date
Application number
TW111144466A
Other languages
English (en)
Chinese (zh)
Inventor
法蘭西斯可 里昂
韋恩 Ｈ 朱靜
Original Assignee
美商安美基公司
美商細胞免疫有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安美基公司, 美商細胞免疫有限責任公司 filed Critical 美商安美基公司
Publication of TW202327653A publication Critical patent/TW202327653A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
TW111144466A 2016-06-15 2017-06-15 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物 TW202327653A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/US16/37708 2016-06-15
PCT/US2016/037708 WO2017217985A1 (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease

Publications (1)

Publication Number Publication Date
TW202327653A true TW202327653A (zh) 2023-07-16

Family

ID=56292925

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111144466A TW202327653A (zh) 2016-06-15 2017-06-15 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物
TW106119998A TW201803591A (zh) 2016-06-15 2017-06-15 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW106119998A TW201803591A (zh) 2016-06-15 2017-06-15 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物

Country Status (11)

Country Link
EP (1) EP3472202A1 (de)
JP (2) JP2019521981A (de)
CN (1) CN109311972A (de)
AR (1) AR108790A1 (de)
AU (2) AU2016411388A1 (de)
BR (1) BR112018076287A2 (de)
CA (1) CA3020894A1 (de)
EA (1) EA201892707A1 (de)
MX (2) MX2018015363A (de)
TW (2) TW202327653A (de)
WO (1) WO2017217985A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991514A1 (ru) 2016-12-21 2019-12-30 Сефалон, Инк. Антитела, которые специфически связываются с ил-15, и их применение
EP3873521A2 (de) * 2018-10-31 2021-09-08 Tiziana Life Sciences PLC Zusammensetzung und verfahren zur behandlung von entzündungs- und autoimmunerkrankungen
MX2024001934A (es) 2021-08-12 2024-03-04 Amgen Inc Formulaciones de anticuerpos.
WO2024028448A1 (en) 2022-08-04 2024-02-08 Calypso Biotech Sa Il-15 inhibitors useful for the treatment of atopic dermatitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
EA015897B1 (ru) * 2003-02-26 2011-12-30 Генмаб А/С Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие
JP2012516153A (ja) * 2009-01-29 2012-07-19 アボット・ラボラトリーズ Ｉｌ−１結合タンパク質
WO2011031986A1 (en) * 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Assays for soluble il-15 receptor alpha
EP2963057A1 (de) * 2014-07-02 2016-01-06 Calypso Biotech SA Antikörper zu IL-15

Also Published As

Publication number Publication date
CN109311972A (zh) 2019-02-05
EP3472202A1 (de) 2019-04-24
AU2016411388A1 (en) 2018-11-08
BR112018076287A2 (pt) 2019-03-26
JP2022001577A (ja) 2022-01-06
MX2024001374A (es) 2024-02-27
MX2018015363A (es) 2019-04-15
WO2017217985A1 (en) 2017-12-21
AU2024205264A1 (en) 2024-08-22
EA201892707A1 (ru) 2019-05-31
CA3020894A1 (en) 2017-12-21
JP2019521981A (ja) 2019-08-08
TW201803591A (zh) 2018-02-01
AR108790A1 (es) 2018-09-26

Similar Documents

Publication Publication Date Title
US20230287094A1 (en) Tgf-beta 3 specific antibodies and methods and uses thereof
JP2023039448A (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
US20190328762A1 (en) Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
JP7389077B2 (ja) インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
JP7459058B2 (ja) Ｃｄ１３７／ｈｅｒ２二重特異性物質とｐｄ－１系阻害物質とを含む併用療法およびその使用法
TW200932268A (en) Binding molecules to the human OX40 receptor
TW201726170A (zh) Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
TW202327653A (zh) 用於治療乳糜瀉、非乳糜瀉麩質敏感、及難治性乳糜瀉之方法及組成物
EP3191120B1 (de) Verwendung von il-17 antagonisten zur hemmung der progression von strukturschäden bei patienten mit psoriatischer arthritis
JP7455749B2 (ja) 頭頸部癌の処置
JP2022532229A (ja) 天疱瘡及び類天疱瘡疾患の治療における抗ＦｃＲｎ抗体の使用
EP3145543A2 (de) Behandlung von eosinophil- oder mastzellenvermittelten erkrankungen
CN112040980A (zh) 用于治疗代谢功能障碍或低瘦蛋白血症的瘦蛋白受体激动剂抗体
KR20220042067A (ko) Gm-csf 길항제를 사용한 암의 치료
US20230312701A1 (en) Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
KR20210131312A (ko) 인간 cd137에 결합하는 항체의 제제 및 이의 용도
KR20210088640A (ko) 암을 치료하기 위한 항-lag3 항체의 투여 요법 및 항-pd-1 항체와의 조합 요법
US20240010729A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
US20230149543A1 (en) Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
WO2021190582A1 (zh) 一种抗ox40抗体药物组合物及其用途
TW202237081A (zh) 抗體及紫杉烷合併療法
JP2023512181A (ja) 癌を治療するためのｅｇｆｒ阻害剤とｒｏｒ１阻害剤の組み合わせ